Latest BMY news

4 Elite Dividend Stocks Yielding Up to 6.14% With Diversified Pipelines That Protect Your Payout

24/7 Wall Street · Wed, 23 Sep 2026 09:01:41 -0400

Patent cliffs have buried lesser pharma dividends, yet these four Big Pharma giants keep raising payouts despite losing blockbuster exclusivities worth billions.

BMY vs GILD: Which Biotech Stock Looks More Attractive Now?

Zacks Investment Research · Mon, 21 Sep 2026 12:56:04 -0400

Bristol Myers' growth portfolio and pipeline advances offer multiple ways to offset legacy-product erosion, while valuation and leverage remain key factors.

Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term

Zacks Investment Research · Mon, 21 Sep 2026 10:41:20 -0400

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder

The Motley Fool · Sun, 20 Sep 2026 08:30:00 -0400

Bristol Myers Squibb's stock is up more than 17% so far this year. The company could be acquired by AstraZeneca.

Can Sotyktu's Long-Term PsA Data Boost Bristol Myers' Prospects?

Zacks Investment Research · Fri, 18 Sep 2026 16:21:09 -0400

Bristol Myers' Sotyktu delivers durable PsA responses for two years, supporting its growth strategy as competition intensifies.

BMY vs. ARGX: Which Stock Is the Better Value Option?

Zacks Investment Research · Fri, 18 Sep 2026 12:40:59 -0400

Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Bristol Myers Squibb (BMY) and argenex SE (ARGX). But which of these two stocks presents investors with the better value opportunity right now?

Are Medical Stocks Lagging Bristol Myers Squibb (BMY) This Year?

Zacks Investment Research · Fri, 18 Sep 2026 10:41:24 -0400

Here is how Bristol Myers Squibb (BMY) and Caris Life Sciences,?Inc. (CAI) have performed compared to their sector so far this year.

Market information is provided for research and visualization and is not investment advice.